Drug maker found liable despite FDA warning label

被引：0
|
作者：
机构：
来源：
Nature | 2009年 / 458卷 / 7235期
关键词：
D O I：
10.1038/458137c
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：137 / 137
相关论文
共 50 条
  • [41] Physicians' Perspectives on FDA Approval Standards and Off-label Drug Marketing
    Kesselheim, Aaron S.
    Woloshin, Steven
    Lu, Zhigang
    Tessema, Frazer A.
    Ross, Kathryn M.
    Schwartz, Lisa M.
    JAMA INTERNAL MEDICINE, 2019, 179 (05) : 707 - 709
  • [42] Donanemab: Conflicts of interest found in FDA committee that approved new Alzheimer's drug
    Lenzer, Jeanne
    Brownlee, Shannon
    BMJ-BRITISH MEDICAL JOURNAL, 2024, 386
  • [43] DRUG-INDUCED NUTRIENT DEPLETION: UNMET CLINICAL NEED OR LABEL WARNING?
    Palthur, M. P.
    ANNALS OF NUTRITION AND METABOLISM, 2013, 63 : 113 - 113
  • [44] Antipsychotic Drug Use Since the FDA Black Box Warning: Survey of Nursing Home Policies
    Lester, Paula
    Kohen, Izchak
    Stefanacci, Richard G.
    Feuerman, Martin
    JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 2011, 12 (08) : 573 - 577
  • [45] Impact of the FDA warning of potential ceftriaxone and calcium interactions on drug use policy in clinical practice
    Esterly, John S.
    Steadman, Emily
    Scheetz, Marc H.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2011, 33 (03) : 537 - 542
  • [46] Impact of the FDA warning of potential ceftriaxone and calcium interactions on drug use policy in clinical practice
    John S. Esterly
    Emily Steadman
    Marc H. Scheetz
    International Journal of Clinical Pharmacy, 2011, 33 : 537 - 542
  • [47] Utility of a US Food and Drug Administration (FDA) label indication for condoms for anal sex
    Siegler, Aaron J.
    Ahlschlager, Lauren
    Rosenthal, Elizabeth M.
    Sullivan, Patrick S.
    Kelley, Colleen F.
    Rosenberg, Eli S.
    Sanchez, Travis H.
    Moore, Renee H.
    Mehta, C. Christina
    Cecil, Michael P.
    SEXUAL HEALTH, 2020, 17 (01) : 91 - 95
  • [48] FDA deems in vitro data on mutations sufficient to expand cystic fibrosis drug label
    Ratner, Mark
    NATURE BIOTECHNOLOGY, 2017, 35 (07) : 606 - 607
  • [49] Few Pediatric Neuropsychiatric Drug Trials despite Common Off-Label Uses
    不详
    PEDIATRIC ANNALS, 2013, 42 (06): : 225 - 225
  • [50] FDA deems in vitro data on mutations sufficient to expand cystic fibrosis drug label
    Mark Ratner
    Nature Biotechnology, 2017, 35 : 606 - 606
12345